^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CD19-CAR-T2 cells
i
Other names: CD19-CAR-T2 cells, CD19-Chimeric Antigen Receptor-T2 cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Southern Medical University
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
6ms
Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement (ASH 2023)
The cells were expanded ex vivo and administered in a single infusion (1×106 or 2×106 CAR T cells per kilogram of body weight) after a conditioning regimen of cyclophosphamide and fludarabine...Conclusion TLR2-costimulated CAR T cell therapy for patients with R/R B cell malignancies with CNS involvement is safe, feasible, and results in high response rates and durable remission in both ALL and NHL patients with CNS disease. The clinical trial was registered at www.clinicaltrials.gov as # NCT04605666.
Clinical • CAR T-Cell Therapy
|
TLR2 (Toll Like Receptor 2)
|
CD19 positive
|
cyclophosphamide • fludarabine IV • CD19-CAR-T2 cells
1year
CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=60, Recruiting, Nanfang Hospital of Southern Medical University | Trial completion date: Jun 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Jun 2023
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 positive
|
CD19-CAR-T2 cells
over3years
CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=60, Recruiting, Nanfang Hospital of Southern Medical University
New P2 trial • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
CD19 positive
|
CD19-CAR-T2 cells
Share via
